Japan’s PMDA Finds CardiAMP Cell Therapy Data Sufficient for Market Clearance
Japan’s PMDA agreed CardiAMP cell therapy’s US clinical safety and efficacy data for ischemic heart failure are likely sufficient to support market clearance in Japan. BioCardia achieved alignment on use indications, introduction strategy and post-marketing study requirements, with a filing timeline pending PMDA’s official feedback.
1. Regulatory Consultation Outcome
BioCardia held a formal clinical consultation with Japan’s PMDA where officials affirmed that CardiAMP’s US-generated safety and efficacy data meet the agency’s requirements for ischemic heart failure treatment. PMDA acknowledged the dataset’s integrity and potential for market clearance.
2. Alignment on Clinical and Commercial Strategy
Both parties agreed on specific indications for use, the acceptability of foreign clinical data, the approach for introducing the therapy into Japanese healthcare settings, and the scope of mandatory post-marketing surveillance studies to monitor long-term safety and efficacy.
3. Next Steps and Timeline
BioCardia will await the official meeting minutes from PMDA to obtain detailed feedback on any remaining data needs and a projected timeline for submission of the regulatory filing toward market approval in Japan.